Retail services. Distressed brands. Cannabis. The small-cap names where the balance sheet is the actual story, the delisting risk is real, and the insider-buy patterns are worth tracking line-by-line.

The pre-deal thesis becomes a new thesis. Different question, same ticker. The integration is where this is won or lost.

Nasdaq minimum-bid-price deficiency. 180-day compliance window. The clock is now the variable.